Short chains of amino acids that can modulate biological targets with high specificity. The GLP-1 receptor agonist revolution (semaglutide, tirzepatide) has made peptides the fastest-growing therapeutic modality by revenue.
Clinical-stage Kailera aims to raise up to $533M on Nasdaq (ticker: KLRA), backed by four GLP-1-based candidates including a once-weekly injectable in Phase 3. The first obesity biotech IPO since Pfizer acquired Metsera for $10B signals renewed investor appetite for the $150B weight-loss market.
Apr 14, 2026 · 5 min read
A systematic review finds six published trials of GLP-1 therapies in Parkinson's disease, with lixisenatide's LIXIPARK trial showing superiority over placebo on motor endpoints. The data fuels a growing hypothesis that incretin-based drugs may slow neurodegeneration — not just metabolic disease.
Apr 13, 2026 · 6 min read
Clarivate highlights orforglipron (oral GLP-1) and retatrutide (GLP-1/GIP/glucagon triple agonist) as defining candidates in an obesity market projected to reach $150B by 2035. The peptide revolution accelerates.
Apr 13, 2026 · 8 min read